PSA Nadir of <0.5 ng/mL Following Brachytherapy for Early-Stage Prostate Adenocarcinoma is Associated With Freedom From Prostate-Specific Antigen Failure-Reference-Cited by-同舟云学术

PSA Nadir of <0.5 ng/mL Following Brachytherapy for Early-Stage Prostate Adenocarcinoma is Associated With Freedom From Prostate-Specific Antigen Failure

Published:2012-06 Issue:2 Volume:83 Page:600-607
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Ko Eric C.,Stone Nelson N.,Stock Richard G.

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference18 articles.

1. Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer;Maffezzini;Eur Urol,2007

2. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy;King;Int J Radiat Oncol Biol Phys,2008

3. In patients experiencing biochemical failure after radiotherapy, pretreatment risk group and PSA velocity predict differences in overall survival and biochemical failure-free interval;Soto;Int J Radiat Oncol Biol Phys,2008

4. Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: Can PSA kinetics distinguish PSA failures from PSA bounces?;Thompson;Int J Radiat Oncol Biol Phys,2010

5. PSA kinetics following I-125 radioactive seed implantation in the treatment of T1-T2 prostate cancer;Iannuzzi;Radiat Oncol Investig,1999

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease control outcomes of stereotactic body radiation therapy or moderate hypo‐fractionation for prostate cancer: Real‐world experience at two Canadian centers;The Prostate;2023-10-25

2. The oncologic and safety outcomes of low-dose-rate brachytherapy for the treatment of prostate cancer;Prostate International;2023-09

3. Racial Analysis of Clinical and Biochemical Outcomes in Patients With Prostate Cancer Treated With Low-Dose-Rate Brachytherapy;International Journal of Radiation Oncology*Biology*Physics;2023-05

4. PSA outcomes and late toxicity of single-fraction HDR brachytherapy and LDR brachytherapy as monotherapy in localized prostate cancer: A phase 2 randomized pilot study;Brachytherapy;2021-11

5. How long is long enough to secure disease control after low-dose-rate brachytherapy in combination with other modalities in intermediate-risk, localized prostate cancer?;International Journal of Clinical Oncology;2021-10-02